Apolonia García-Patterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Apolonia García-Patterson has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Rosa Corcoy
Department of Medicine Universitat Autònoma de Barcelona Barcelona Spain
5 shared publications - Anna Aulinas
Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic/Manresa , 08500 Catalonia
2 shared publications Carmen Medina
Institut d'Investigacio Biomedica Sant Pau
2 shared publicationsEsther López
Institut d'Investigacio Biomedica Sant Pau
2 shared publications- Ivan Solà
Iberoamerican Cochrane Centre Barcelona Spain
2 shared publications Montserrat Balsells
Independent Investigator Barcelona Spain
2 shared publications
Latest Publications
- Open Access
- 17 November 2022
- Published by Wiley in Diabetic Medicine
- Vol. 40 (1) , e14998
Impact of gestational diabetes mellitus treatment on medium/long‐term outcomes after pregnancy: A systematic review and meta‐analysis
Aim: We aimed to evaluate the effect of gestational diabetes mellitus (GDM) treatment on medium/long‐term outcomes both the mother and offspring.Methods: We performed a systematic review on randomized clinical trials addressing specific treatment of women with GDM versus usual care and its impact on maternal and offspring outcomes at medium/long‐term. MEDLINE, EMBASE and CENTRAL were searched from inception to 8 October 2021. Outcome variables: maternal (diabetes, metabolic syndrome, 12 secondary); offspring (diabetes, impaired fasting glucose, impaired glucose tolerance, high body mass index, 15 secondary). Risk of bias was assessed with Cochrane tool and aggregation performed with Revman 5.4.Results: We included five studies (1140 women, 767 offspring) with follow‐up ranging 4–16 years after delivery. GDM treatment likely does not reduce risk of maternal diabetes (RR 1.00; [95% CI 0.82–1.23]) and may not reduce that of metabolic syndrome (RR 0.93; [95% CI 0.71–1.22]). We obtained very uncertain evidence that treatment may increase maternal HDL‐cholesterol. Findings showed that GDM treatment may not have an impact on infants' outcomes (RRs 0.79; [95% CI 0.39–1.69] for impaired fasting glucose; RR 0.91; [95% CI 0.74–1.12] for body mass index >85th centile and 0.89; [95% CI 0.65–1.22] for body mass index >95th centile respectively).Conclusions: With current evidence is uncertain if specific treatment of women with GDM has an impact on medium/long‐term metabolic outcomes either in the mother or in the offspring. These results add evidence to the recommendation of systematically reevaluating mother and offspring after delivery.Registration: OSF, DOI 10.17605/OSF.IO/KFN79
- 17 November 2022
- Published by Wiley in Diabetic Medicine
- Vol. 40 (1) , e14998
Open AccessImpact of gestational diabetes mellitus treatment on medium/long‐term outcomes after pregnancy: A systematic review and meta‐analysis
Aim: We aimed to evaluate the effect of gestational diabetes mellitus (GDM) treatment on medium/long‐term outcomes both the mother and offspring.Methods: We performed a systematic review on randomized clinical trials addressing specific treatment of women with GDM versus usual care and its impact on maternal and offspring outcomes at medium/long‐term. MEDLINE, EMBASE and CENTRAL were searched from inception to 8 October 2021. Outcome variables: maternal (diabetes, metabolic syndrome, 12 secondary); offspring (diabetes, impaired fasting glucose, impaired glucose tolerance, high body mass index, 15 secondary). Risk of bias was assessed with Cochrane tool and aggregation performed with Revman 5.4.Results: We included five studies (1140 women, 767 offspring) with follow‐up ranging 4–16 years after delivery. GDM treatment likely does not reduce risk of maternal diabetes (RR 1.00; [95% CI 0.82–1.23]) and may not reduce that of metabolic syndrome (RR 0.93; [95% CI 0.71–1.22]). We obtained very uncertain evidence that treatment may increase maternal HDL‐cholesterol. Findings showed that GDM treatment may not have an impact on infants' outcomes (RRs 0.79; [95% CI 0.39–1.69] for impaired fasting glucose; RR 0.91; [95% CI 0.74–1.12] for body mass index >85th centile and 0.89; [95% CI 0.65–1.22] for body mass index >95th centile respectively).Conclusions: With current evidence is uncertain if specific treatment of women with GDM has an impact on medium/long‐term metabolic outcomes either in the mother or in the offspring. These results add evidence to the recommendation of systematically reevaluating mother and offspring after delivery.Registration: OSF, DOI 10.17605/OSF.IO/KFN79
- Open Access
- 23 March 2022
- Published by Universitat Autonoma de Barcelona
Hypopituitarism and Pregnancy : Clinical Characteristics, Management and Pregnancy Outcome
The dataset for this study contains clinical variables of the patients with prepregnancy hypopituitarism (at least two pituitary hormones requiring substitutive treatment) and confirmed pregnancy. Briefly, information of the following variables was collected: pituitary disease and treatment, fertility, clinical assessment during pregnancy, pregnancy and neonatal outcomes.
- 23 March 2022
- Published by Universitat Autonoma de Barcelona
Open AccessHypopituitarism and Pregnancy : Clinical Characteristics, Management and Pregnancy Outcome
The dataset for this study contains clinical variables of the patients with prepregnancy hypopituitarism (at least two pituitary hormones requiring substitutive treatment) and confirmed pregnancy. Briefly, information of the following variables was collected: pituitary disease and treatment, fertility, clinical assessment during pregnancy, pregnancy and neonatal outcomes.
- Open Access
- 30 November 2021
- Published by Springer Nature in Pituitary
- Vol. 25 (2) , 275-284
Hypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome
Purpose: To describe the clinical characteristics, management and pregnancy outcome of women with prepregnancy hypopituitarism (HYPO) that received care at our center. Methods: Retrospective study describing 12 pregnancies in women with prepregnancy HYPO (two or more pituitary hormonal deficiencies under replacement treatment) that received care during pregnancy at Hospital Santa Creu i Sant Pau. Clinical characteristics, management and pregnancy outcome were systematically collected. Results: Average patients’ age was 35 years and HYPO duration at the beginning of pregnancy was 19 years. The most frequent cause of HYPO was surgical treatment of a sellar mass (8 pregnancies). Eight pregnancies were in primigravid women and 10 required assisted reproductive techniques. The hormonal deficits before pregnancy were as follows: GH in 12 women, TSH in 10, gonadotropin in 9, ACTH in 5 and ADH in 2. All deficits were under hormonal substitution except for GH deficit in 4 pregnancies. During pregnancy, 4 new deficits were diagnosed. The dosage of replacement treatment for TSH, ACTH and ADH deficits was increased and GH was stopped. Average gestational age at birth was 40 weeks, gestational weight gain was excessive in 9 women, 8 patients required induction/elective delivery and cesarean section was performed in 6. Average birthweight was 3227 g. No major complications were observed. Five women were breastfeeding at discharge. Conclusions: In this group of women with long-standing HYPO, with careful clinical management (including treatment of new-onset hormonal deficits) pregnancy outcome was satisfactory but with a high rate of excessive gestational weight gain and cesarean section.
- 30 November 2021
- Published by Springer Nature in Pituitary
- Vol. 25 (2) , 275-284
Open AccessHypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome
Purpose: To describe the clinical characteristics, management and pregnancy outcome of women with prepregnancy hypopituitarism (HYPO) that received care at our center. Methods: Retrospective study describing 12 pregnancies in women with prepregnancy HYPO (two or more pituitary hormonal deficiencies under replacement treatment) that received care during pregnancy at Hospital Santa Creu i Sant Pau. Clinical characteristics, management and pregnancy outcome were systematically collected. Results: Average patients’ age was 35 years and HYPO duration at the beginning of pregnancy was 19 years. The most frequent cause of HYPO was surgical treatment of a sellar mass (8 pregnancies). Eight pregnancies were in primigravid women and 10 required assisted reproductive techniques. The hormonal deficits before pregnancy were as follows: GH in 12 women, TSH in 10, gonadotropin in 9, ACTH in 5 and ADH in 2. All deficits were under hormonal substitution except for GH deficit in 4 pregnancies. During pregnancy, 4 new deficits were diagnosed. The dosage of replacement treatment for TSH, ACTH and ADH deficits was increased and GH was stopped. Average gestational age at birth was 40 weeks, gestational weight gain was excessive in 9 women, 8 patients required induction/elective delivery and cesarean section was performed in 6. Average birthweight was 3227 g. No major complications were observed. Five women were breastfeeding at discharge. Conclusions: In this group of women with long-standing HYPO, with careful clinical management (including treatment of new-onset hormonal deficits) pregnancy outcome was satisfactory but with a high rate of excessive gestational weight gain and cesarean section.
- Top Cited PapersOpen Access
- 14 June 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (7) , 1346-1361
Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight
OBJECTIVE Medical nutrition therapy is a mainstay of gestational diabetes mellitus (GDM) treatment. However, data are limited regarding the optimal diet for achieving euglycemia and improved perinatal outcomes. This study aims to investigate whether modified dietary interventions are associated with improved glycemia and/or improved birth weight outcomes in women with GDM when compared with control dietary interventions. RESEARCH DESIGN AND METHODS Data from published randomized controlled trials that reported on dietary components, maternal glycemia, and birth weight were gathered from 12 databases. Data were extracted in duplicate using prespecified forms. RESULTS From 2,269 records screened, 18 randomized controlled trials involving 1,151 women were included. Pooled analysis demonstrated that for modified dietary interventions when compared with control subjects, there was a larger decrease in fasting and postprandial glucose (−4.07 mg/dL [95% CI −7.58, −0.57]; P = 0.02 and −7.78 mg/dL [95% CI −12.27, −3.29]; P = 0.0007, respectively) and a lower need for medication treatment (relative risk 0.65 [95% CI 0.47, 0.88]; P = 0.006). For neonatal outcomes, analysis of 16 randomized controlled trials including 841 participants showed that modified dietary interventions were associated with lower infant birth weight (−170.62 g [95% CI −333.64, −7.60]; P = 0.04) and less macrosomia (relative risk 0.49 [95% CI 0.27, 0.88]; P = 0.02). The quality of evidence for these outcomes was low to very low. Baseline differences between groups in postprandial glucose may have influenced glucose-related outcomes. As well, relatively small numbers of study participants limit between-diet comparison. CONCLUSIONS Modified dietary interventions favorably influenced outcomes related to maternal glycemia and birth weight. This indicates that there is room for improvement in usual dietary advice for women with GDM.
- 14 June 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (7) , 1346-1361
Top Cited PapersOpen AccessGestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight
OBJECTIVE Medical nutrition therapy is a mainstay of gestational diabetes mellitus (GDM) treatment. However, data are limited regarding the optimal diet for achieving euglycemia and improved perinatal outcomes. This study aims to investigate whether modified dietary interventions are associated with improved glycemia and/or improved birth weight outcomes in women with GDM when compared with control dietary interventions. RESEARCH DESIGN AND METHODS Data from published randomized controlled trials that reported on dietary components, maternal glycemia, and birth weight were gathered from 12 databases. Data were extracted in duplicate using prespecified forms. RESULTS From 2,269 records screened, 18 randomized controlled trials involving 1,151 women were included. Pooled analysis demonstrated that for modified dietary interventions when compared with control subjects, there was a larger decrease in fasting and postprandial glucose (−4.07 mg/dL [95% CI −7.58, −0.57]; P = 0.02 and −7.78 mg/dL [95% CI −12.27, −3.29]; P = 0.0007, respectively) and a lower need for medication treatment (relative risk 0.65 [95% CI 0.47, 0.88]; P = 0.006). For neonatal outcomes, analysis of 16 randomized controlled trials including 841 participants showed that modified dietary interventions were associated with lower infant birth weight (−170.62 g [95% CI −333.64, −7.60]; P = 0.04) and less macrosomia (relative risk 0.49 [95% CI 0.27, 0.88]; P = 0.02). The quality of evidence for these outcomes was low to very low. Baseline differences between groups in postprandial glucose may have influenced glucose-related outcomes. As well, relatively small numbers of study participants limit between-diet comparison. CONCLUSIONS Modified dietary interventions favorably influenced outcomes related to maternal glycemia and birth weight. This indicates that there is room for improvement in usual dietary advice for women with GDM.
- 1 December 2004
- Published by Springer Nature in Acta Diabetologica
- Vol. 41 (4) , 154-157
Is selective screening for gestational diabetes mellitus worthwhile everywhere?
We assessed if selective screening for gestational diabetes mellitus (GDM) as recommended by the Fourth Workshop on GDM is worthwhile in our centre. Detection is performed using universal screening in three pregnancy periods using the tests recommended by the first three Workshops. We have analysed the prevalence of low-risk characteristics for GDM in the 917 women delivering in the centre in 1992 and in the whole cohort of 1635 women with GDM delivering between 1986 and 1998. The rate of women with all low risk characteristics was 7.0% among the general pregnant population and 1.3% in the cohort of women with GDM (p<0.001). We conclude that in our population, selective screening of GDM is reliable in identifying women at low risk of GDM, but since only a negligible subset of the pregnant population would not need to be screened, adherence to these guidelines would make the screening policy unnecessarily complicated.
- 1 December 2004
- Published by Springer Nature in Acta Diabetologica
- Vol. 41 (4) , 154-157
Is selective screening for gestational diabetes mellitus worthwhile everywhere?
We assessed if selective screening for gestational diabetes mellitus (GDM) as recommended by the Fourth Workshop on GDM is worthwhile in our centre. Detection is performed using universal screening in three pregnancy periods using the tests recommended by the first three Workshops. We have analysed the prevalence of low-risk characteristics for GDM in the 917 women delivering in the centre in 1992 and in the whole cohort of 1635 women with GDM delivering between 1986 and 1998. The rate of women with all low risk characteristics was 7.0% among the general pregnant population and 1.3% in the cohort of women with GDM (p<0.001). We conclude that in our population, selective screening of GDM is reliable in identifying women at low risk of GDM, but since only a negligible subset of the pregnant population would not need to be screened, adherence to these guidelines would make the screening policy unnecessarily complicated.